

EXHIBIT C



FOLEY & LARDNER LLP

May 21, 2007

John C. Martin
Pfizer, Inc.
150 East 42nd Street, Mail Stop 49
New York, New York 10017

RECEIVED

MAY 29 2007

LA JOLLA PATENT DEPT

ATTORNEYS AT LAW

WASHINGTON HARBOUR
3000 K STREET, N.W., SUITE 500
WASHINGTON, D.C. 20007-5143
202.672.5300 TEL
202.672.5399 FAX
www.foley.com

WRITER'S DIRECT LINE
202.672.5558
mburrell@foley.com EMAIL

CLIENT/MATTER NUMBER
999100-0160

Re: Forwarding of Client Mail

Dear Mr. Martin:

Enclosed please find mail recently received at Foley & Lardner, LLP relating to the matters outlined below. It has been determined that this information relates to the client who transferred their business to you. As a courtesy, we are forwarding this mail to your office. In order to avoid any confusion due to misdirected mail, we recommend that you notify the sender that you are the counsel representing the client and all future mailings should be addressed to Pfizer, Inc..

Client/Matter Name	Document(s) Description
US Patent Application 09/857,797; Filed 9/13/01; Our reference 017227/0175	Notice of Abandonment from the PTO; Dated 1/24/07; Received by Foley & Lardner LLP on 1/26/07

We have not copied any of the materials contained in these files. We are relying upon your representation that Foley & Lardner, LLP will have the right to review and copy these files in the future upon reasonable notice.

Please sign this letter within 20 days of receipt of this material and mail it to my attention or fax it to me at the number listed above. Your signature indicates:

1. You have received all the items listed on the index.
2. Pfizer, Inc. is now responsible for all further matters involving the subject case and that you will file a new power of attorney form with the PTO revoking all prior powers of attorney.

Thank you for your assistance in this matter. Please contact me if you have any questions.

BOSTON
BRUSSELS
CHICAGO
DETROIT
JACKSONVILLE

LOS ANGELES
MADISON
MILWAUKEE
NEW YORK
ORLANDO

SACRAMENTO
SAN DIEGO
SAN DIEGO/DEL MAR
SAN FRANCISCO
SILICON VALLEY

TALLAHASSEE
TAMPA
TOKYO
WASHINGTON, D.C.

WASH_1632727.4



FOLEY & LARDNER LLP Page 2

Sincerely,

Michael Burrell
IP Records Supervisor

NOTICE & ACKNOWLEDGEMENT OF FILE RECEIPT

The documents/client files described below are being sent to Pfizer, Inc., with this acknowledgement form. Please sign the form to acknowledgement receipt of the documents/client files. In addition, the sender, Foley & Lardner LLP, retains the right to view and copy any documents, client files and/or media containing electronic records or documents, that are served on you, as long as proper and reasonable notice is given to Pfizer, Inc.. Pfizer, Inc. is responsible for verifying the accuracy and completeness of data received from Foley & Lardner LLP by comparing it with each file before making any use of the data in connection with matters in which such accuracy and completeness could be of consequence, and agrees that Foley & Lardner LLP should not be held responsible for any use made of this data.

I agree with the statements listed above, and I received the following from Foley & Lardner, LLP:

1. Index of client mail transferred to Pfizer, Inc.
2. Original client mail for the matter listed above.

RECEIVED

MAY 29 2007

Date this acknowledgement is signed: _____

Jani ce Sanchez
(To be completed by the Recipient)

LA JOLLA PATENT DEPT

Jani ce Sanchez

(Print Name of Person Acknowledging Receipt)

Jani ce Sanchez

(Signature of Person Acknowledging Receipt)

Confirmation Report - Memory Send

Page : 001
Date & Time: May-29-07 09:56am
Line 1 : +8586788233
Line 2 :
Machine ID : pfizer la jolla

Job number : 882
Date : May-29 09:55am
To : 8912026725399
Number of pages : 002
Start time : May-29 09:55am
End time : May-29 09:56am
Pages sent : 002
Status : OK

Job number : 882

*** SEND SUCCESSFUL ***

FOLEY
FOLEY & LARDNER LLP

May 21, 2007

John C. Martin
Pfizer, Inc.
150 East 42nd Street, Mail Stop 49
New York, New York 10017

RECEIVED

MAY 29 2007

LA JOLLA PATENT DEPT

ATTORNEYS AT LAW
WASHINGTON HARBOUR
8000 K STREET, N.W., SUITE 500
WASHINGTON, D.C. 20007-8143
202.672.5500 TEL
202.672.0399 FAX
www.foley.com

WRITER'S DIRECT LINE
202.672.5555
mburrell@foley.com EMAIL
CLIENT/MATTER NUMBER
999100-0180

Re: Forwarding of Client Mail

Dear Mr. Martin:

Enclosed please find mail recently received at Foley & Lardner, LLP relating to the matters outlined below. It has been determined that this information relates to the client who transferred their business to you. As a courtesy, we are forwarding this mail to your office. In order to avoid any confusion due to misdirected mail, we recommend that you notify the sender that you are the counsel representing the client and all future mailings should be addressed to Pfizer, Inc..

Client/Matter Name	Document(s) Description
US Patent Application 09/837,797; Filed 9/13/01; Our reference 017227/0175	Notice of Abandonment from the PTO; Dated 1/24/07; Received by Foley & Lardner LLP on 1/26/07

We have not copied any of the materials contained in these files. We are relying upon your representation that Foley & Lardner, LLP will have the right to review and copy these files in the future upon reasonable notice.

Please sign this letter within 20 days of receipt of this material and mail it to my attention or fax it to me at the number listed above. Your signature indicates:

1. You have received all the items listed on the index.
2. Pfizer, Inc. is now responsible for all further matters involving the subject case and that you will file a new power of attorney form with the PTO revoking all prior powers of attorney.

Thank you for your assistance in this matter. Please contact me if you have any questions.

BOSTON
BRUSSELS
CHICAGO
DETROIT
JACKSONVILLE

LOS ANGELES
MADISON
MILWAUKEE
NEW YORK
ORLANDO

SACRAMENTO
SAN DIEGO
SAN DIEGO/DEL MAR
SAN FRANCISCO
SILICON VALLEY

TALLAHASSEE
TAMPA
TOKYO
WASHINGTON, D.C.

WASH_1632727.4

Foley & Lardner - LegalKEY

Client/Matter File Index

5/21/2007 7:42:33PM

Client	017227	Client Name	DAVIES & COLLISON
Matter	0175	Matter Name	US SERIAL NO. 09/857,797 JOHN WALKER BASED ON PCT/AU99/01167 FILED 12/24/99 IMPROVED
Date Opened	5/29/2001	Area Of Law	SAPONIN ADJUVANT COMPOSITIONS AND ...
Status	ACTIVE	Office	Pre FLOW Matter
			Washington D. C.

Folder Title	Folder Key	Location	Folder Barcode	Status	Comments
--------------	------------	----------	----------------	--------	----------

MAIL FORWARDED -	WASH	CORRES2-0001	Washington Records	F6402161	A
------------------	------	--------------	--------------------	----------	---

Notice of Abandonment from the PTO; Dated
1/24/07; Received by Foley & Lardner LLP on
1/26/07



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/857,797	09/13/2001	John Walker	017227-0175	9643
22428 7590 01/24/2007 FOLEY AND LARDNER LLP SUITE 500 3000 K STREET NW WASHINGTON, DC 20007			EXAMINER KIM, YUNSOO	
			ART UNIT 1644	PAPER NUMBER
			MAIL DATE 01/24/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

Notice of Abandonment

Application No.

09/857,797

Examiner

Yunsoo Kim

Applicant(s)

WALKER, JOHN

Art Unit

1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

This application is abandoned in view of:

1. ☒ Applicant's failure to timely file a proper reply to the Office letter mailed on 25 November 2005.
 - (a) ☐ A reply was received on _____ (with a Certificate of Mailing or Transmission dated _____), which is after the expiration of the period for reply (including a total extension of time of _____ month(s)) which expired on _____.
 - (b) ☐ A proposed reply was received on _____, but it does not constitute a proper reply under 37 CFR 1.113 (a) to the final rejection.
(A proper reply under 37 CFR 1.113 to a final rejection consists only of: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114).
 - (c) ☒ A reply was received on 25 May 2006 but it does not constitute a proper reply, or a bona fide attempt at a proper reply, to the non-final rejection. See 37 CFR 1.85(a) and 1.111. (See explanation in box 7 below).
 - (d) ☐ No reply has been received.
2. ☐ Applicant's failure to timely pay the required issue fee and publication fee, if applicable, within the statutory period of three months from the mailing date of the Notice of Allowance (PTOL-85).
 - (a) ☐ The issue fee and publication fee, if applicable, was received on _____ (with a Certificate of Mailing or Transmission dated _____), which is after the expiration of the statutory period for payment of the issue fee (and publication fee) set in the Notice of Allowance (PTOL-85).
 - (b) ☐ The submitted fee of \$_____ is insufficient. A balance of \$_____ is due.
The issue fee required by 37 CFR 1.18 is \$_____. The publication fee, if required by 37 CFR 1.18(d), is \$_____.
 - (c) ☐ The issue fee and publication fee, if applicable, has not been received.
3. ☐ Applicant's failure to timely file corrected drawings as required by, and within the three-month period set in, the Notice of Allowability (PTO-37).
 - (a) ☐ Proposed corrected drawings were received on _____ (with a Certificate of Mailing or Transmission dated _____), which is after the expiration of the period for reply.
 - (b) ☐ No corrected drawings have been received.
4. ☐ The letter of express abandonment which is signed by the attorney or agent of record, the assignee of the entire interest, or all of the applicants.
5. ☐ The letter of express abandonment which is signed by an attorney or agent (acting in a representative capacity under 37 CFR 1.34(a)) upon the filing of a continuing application.
6. ☐ The decision by the Board of Patent Appeals and Interference rendered on _____ and because the period for seeking court review of the decision has expired and there are no allowed claims.
7. ☒ The reason(s) below:

As Applicants' reply filed on 5/25/06 does not constitute a proper reply and a notice to non-compliant amendment has been sent on 6/2/06. Confirmed with Mr. J. Martin that no reply has been filed to the notice to non-compliant amendment on 1/17/07


CHRISTINA CHAN

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

Petitions to revive under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonment under 37 CFR 1.181, should be promptly filed to minimize any negative effects on patent term.

EXHIBIT D

Donahue, Victor

From: Donahue, Victor
Sent: Thursday, August 02, 2007 3:40 PM
To: Zajac, Justyna
Subject: EFR hunt

J:

For PC22141 and 22142, please check in EFR as to any recent (6 month) office actions for EP, Japan and USA. You may ignore EP-22142 as I am working on that today.

I have a feeling office actions have been been issued that have not popped up in my EFR in-box. Thank you.

E. Victor Donahue, Ph.D.
Senior Corporate Counsel
Pfizer Inc.
150 East 42nd Street, 5th floor, mailstop 150-5-49
New York, NY 10017
(212) 733-2739 (phone)
(212) 573-1939 (fax)
victor.donahue@pfizer.com

10/26/2007

Donahue, Victor

From: Donahue, Victor
Sent: Friday, October 12, 2007 1:41 PM
To: Zajac, Justyna
Subject: status-recheck

J:

Please recheck EFR and PAIR that there is not a pending office action in PC22141A (I hope there is not also a "B") for USA that needs a response. We are well overdue for the PTO to send us one, thanks, V

E. Victor Donahue, Ph.D.
Senior Corporate Counsel
Pfizer Inc.
150 East 42nd Street, 5th floor, mailstop 150-5-49
New York, NY 10017
(212) 733-2739 (phone)
(212) 573-1939 (fax)
victor.donahue@pfizer.com

10/26/2007